Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This research is being done to determine the efficacy of selpercatinib to restore radioactive
iodine (I-131) uptake and allow for I-131 treatment in people with RET fusion-positive
radioiodine-refractory thyroid cancer.
This research study involves the study drug selpercatinib in combination with standard of
care treatments, I-131 and thyrotropin alfa (rhTSH).